Claude-Henry Volmar, Ph.D. - Publications

Affiliations: 
2011- Center for Therapeutic Innovation and Department of Psychiatry University of Miami Miller School of Medicine, Miami, FL, United States 
Area:
Drug Discovery, Neuroscience, Cancer Biology, Precision Medicine, Molecular Biology, Cell Biology

45 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Kemper C, Benham D, Brothers S, Wahlestedt C, Volmar CH, Bennett D, Hayward M. Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL ). Aaps Open. 8: 11. PMID 35789594 DOI: 10.1186/s41120-022-00058-1  0.441
2022 Dennison JL, Volmar CH, Modarresi F, Ke D, Wang J, Gravel E, Hammond-Vignini S, Li Z, Timmons JA, Lohse I, Hayward MA, Brothers SP, Wahlestedt C. Erratum to: JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model. Journal of Alzheimer's Disease : Jad. PMID 35723129 DOI: 10.3233/JAD-229006  0.511
2022 Timmons JA, Anighoro A, Brogan RJ, Stahl J, Wahlestedt C, Farquhar DG, Taylor-King J, Volmar CH, Kraus WE, Phillips SM. A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease. Elife. 11. PMID 35037854 DOI: 10.7554/eLife.68832  0.464
2022 Dennison JL, Volmar CH, Ke D, Wang J, Gravel E, Hammond-Vignini S, Li Z, Timmons JA, Lohse I, Hayward MA, Brothers SP, Wahlestedt C. JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model. Journal of Alzheimer's Disease : Jad. PMID 35034905 DOI: 10.3233/JAD-215370  0.529
2021 Modarresi F, Pedram Fatemi R, Razavipour SF, Ricciardi N, Makhmutova M, Khoury N, Magistri M, Volmar CH, Wahlestedt C, Faghihi MA. A novel knockout mouse model of the noncoding antisense () gene displays increased endogenous Bdnf protein and improved memory function following exercise. Heliyon. 7: e07570. PMID 34377851 DOI: 10.1016/j.heliyon.2021.e07570  0.43
2021 Dennison JL, Ricciardi NR, Lohse I, Volmar CH, Wahlestedt C. Sexual Dimorphism in the 3xTg-AD Mouse Model and Its Impact on Pre-Clinical Research. Journal of Alzheimer's Disease : Jad. PMID 33459720 DOI: 10.3233/JAD-201014  0.499
2020 Kuznetsoff JN, Owens DA, Lopez A, Rodriguez DA, Chee NT, Kurtenbach S, Bilbao D, Roberts ER, Volmar CH, Wahlestedt C, Brothers SP, Harbour JW. Dual screen for efficacy and toxicity identifies HDAC inhibitor with distinctive activity spectrum for BAP1-mutant uveal melanoma. Molecular Cancer Research : McR. PMID 33077485 DOI: 10.1158/1541-7786.MCR-20-0434  0.442
2020 Owens DA, Kuznetsov JN, Lopez A, Kurtenbach S, Bilbao D, Roberts ER, Volmar C, Wahlestedt CR, Harbour JW. Abstract 4025: New candidate therapy for BAP1-mutant cancer identified using novel screen Cancer Research. 80: 4025-4025. DOI: 10.1158/1538-7445.Am2020-4025  0.507
2019 Lohse I, Azzam DJ, Al-Ali H, Volmar CH, Brothers SP, Ince TA, Wahlestedt C. Ovarian Cancer Treatment Stratification Using Drug Sensitivity Testing. Anticancer Research. 39: 4023-4030. PMID 31366484 DOI: 10.21873/Anticanres.13558  0.414
2019 Timmons JA, Volmar CH, Crossland H, Phillips BE, Sood S, Janczura KJ, Törmäkangas T, Kujala UM, Kraus WE, Atherton PJ, Wahlestedt C. Longevity-related molecular pathways are subject to midlife "switch" in humans. Aging Cell. e12970. PMID 31168962 DOI: 10.1111/Acel.12970  0.438
2019 Mustafi S, Camarena V, Qureshi R, Yoon H, Volmar CH, Huff TC, Sant DW, Zheng L, Brothers SP, Wahlestedt C, Slingerland J, Wang G. Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer. Ebiomedicine. PMID 30975544 DOI: 10.1016/J.Ebiom.2019.04.006  0.407
2019 Bagheri A, Habibzadeh P, Razavipour SF, Volmar CH, Chee NT, Brothers SP, Wahlestedt C, Mowla SJ, Faghihi MA. HDAC Inhibitors Induce Expression and Promote Neurite Outgrowth in Human Neural Progenitor Cells-Derived Neurons. International Journal of Molecular Sciences. 20. PMID 30841499 DOI: 10.3390/ijms20051109  0.435
2018 Janczura KJ, Volmar CH, Wahlestedt C. Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue. Journal of Visualized Experiments : Jove. PMID 30582583 DOI: 10.3791/58648  0.415
2018 Stathias V, Jermakowicz AM, Maloof ME, Forlin M, Walters W, Suter RK, Durante MA, Williams SL, Harbour JW, Volmar CH, Lyons NJ, Wahlestedt C, Graham RM, Ivan ME, Komotar RJ, et al. Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nature Communications. 9: 5315. PMID 30552330 DOI: 10.1038/S41467-018-07659-Z  0.47
2018 Janczura KJ, Volmar CH, Sartor GC, Rao SJ, Ricciardi NR, Lambert G, Brothers SP, Wahlestedt C. Inhibition of HDAC3 reverses Alzheimer's disease-related pathologies in vitro and in the 3xTg-AD mouse model. Proceedings of the National Academy of Sciences of the United States of America. PMID 30397132 DOI: 10.1073/Pnas.1805436115  0.615
2018 Lohse I, Al-Ali H, Volmar CH, D Alvarez Trotta A, Brothers SP, Capobianco AJ, Wahlestedt C. Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma. Plos One. 13: e0203173. PMID 30212533 DOI: 10.1371/Journal.Pone.0203173  0.418
2018 Timmons JA, Atherton PJ, Larsson O, Sood S, Blokhin IO, Brogan RJ, Volmar CH, Josse AR, Slentz C, Wahlestedt C, Phillips SM, Phillips BE, Gallagher IJ, Kraus WE. A coding and non-coding transcriptomic perspective on the genomics of human metabolic disease. Nucleic Acids Research. PMID 29986096 DOI: 10.1093/Nar/Gky570  0.431
2018 Brothers S, Volmar C, Bodamer O, Hayward M, Wahlestedt C. Novel small molecule therapy development for MPS I Molecular Genetics and Metabolism. 123: S26. DOI: 10.1016/J.Ymgme.2017.12.043  0.453
2018 Volmar C, Salah-Uddin H, Janczura KJ, Halley P, Lambert G, Wodrich A, Manoah S, Patel NH, Sartor GC, Mehta N, Miles NT, Desse S, Dorcius D, Cameron MD, Brothers SP, et al. 112. Multipronged HDAC Strategy for Alzheimer’s Disease Biological Psychiatry. 83: S46. DOI: 10.1016/J.Biopsych.2018.02.130  0.5
2017 Mustafi S, Camarena V, Volmar CH, Huff TC, Sant DW, Brothers SP, Liu ZJ, Wahlestedt C, Wang G. Vitamin C sensitizes melanoma to BET inhibitors. Cancer Research. PMID 29180474 DOI: 10.1158/0008-5472.Can-17-2040  0.465
2017 Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers SP, Abbasi T, Trent J, et al. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. Leukemia Research. 64: 34-41. PMID 29175379 DOI: 10.1016/J.Leukres.2017.11.008  0.418
2017 Volmar CH, Salah-Uddin H, Janczura KJ, Halley P, Lambert G, Wodrich A, Manoah S, Patel NH, Sartor GC, Mehta N, Miles NTH, Desse S, Dorcius D, Cameron MD, Brothers SP, et al. M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory. Proceedings of the National Academy of Sciences of the United States of America. 114: E9135-E9144. PMID 29073110 DOI: 10.1073/Pnas.1707544114  0.539
2016 Magistri M, Velmeshev D, Makhmutova M, Patel P, Sartor GC, Volmar CH, Wahlestedt C, Faghihi MA. The BET-bromodomain inhibitor JQ1 reduces inflammation and tau phosphorylation at Ser396 in the brain of the 3xTg model of Alzheimer's disease. Current Alzheimer Research. PMID 27117003 DOI: 10.2174/1567205013666160427101832  0.542
2016 Volmar CH, Wahlestedt C, Brothers SP. Orphan diseases: state of the drug discovery art. Wiener Medizinische Wochenschrift (1946). PMID 26819216 DOI: 10.1007/s10354-015-0423-0  0.447
2015 Pastori C, Kapranov P, Penas C, Peschansky V, Volmar CH, Sarkaria JN, Bregy A, Komotar R, St Laurent G, Ayad NG, Wahlestedt C. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proceedings of the National Academy of Sciences of the United States of America. 112: 8326-31. PMID 26111795 DOI: 10.1073/Pnas.1424220112  0.523
2015 Zeier Z, Esanov R, Belle KC, Volmar CH, Johnstone AL, Halley P, DeRosa BA, Khoury N, van Blitterswijk M, Rademakers R, Albert J, Brothers SP, Wuu J, Dykxhoorn DM, Benatar M, et al. Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Experimental Neurology. 271: 241-50. PMID 26099177 DOI: 10.1016/J.Expneurol.2015.06.017  0.48
2015 Azzam D, Volmar C, Hassan A, Perez A, Watts JM, Vargas F, Elias R, Vega F, Zelent A, Cogle CR, Wahlestedt C, Swords RT. A Patient-Specific Ex Vivo Screening Platform for Personalized Acute Myeloid Leukemia (AML) Therapy Blood. 126: 1352-1352. DOI: 10.1182/Blood.V126.23.1352.1352  0.499
2015 Volmar C, Wahlestedt C. Histone deacetylases (HDACs) and brain function Neuroepigenetics. 1: 20-27. DOI: 10.1016/j.nepig.2014.10.002  0.411
2015 Zeier Z, Esanov R, Belle KC, Volmar CH, Johnstone AL, Halley P, DeRosa BA, Khoury N, van Blitterswijk M, Rademakers R, Albert J, Brothers SP, Wuu J, Dykxhoorn DM, Benatar M, et al. Bromodomain inhibitors regulate the C9ORF72 locus in ALS Experimental Neurology. 271: 241-250. DOI: 10.1016/j.expneurol.2015.06.017  0.389
2014 Long J, Li B, Rodriguez-Blanco J, Pastori C, Volmar CH, Wahlestedt C, Capobianco A, Bai F, Pei XH, Ayad NG, Robbins DJ. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. The Journal of Biological Chemistry. 289: 35494-502. PMID 25355313 DOI: 10.1074/Jbc.M114.595348  0.46
2014 Plotkin A, Volmar CH, Wahlestedt C, Ayad N, El-Ashry D. Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs. Breast Cancer Research and Treatment. 147: 249-63. PMID 25129342 DOI: 10.1007/S10549-014-3093-5  0.413
2014 Pastori C, Daniel M, Penas C, Volmar CH, Johnstone AL, Brothers SP, Graham RM, Allen B, Sarkaria JN, Komotar RJ, Wahlestedt C, Ayad NG. BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics : Official Journal of the Dna Methylation Society. 9: 611-20. PMID 24496381 DOI: 10.4161/Epi.27906  0.449
2011 Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, Laporte V, Ganey J, Beaulieu-Abdelahad D, Ait-Ghezala G, Crawford F, Mullan MJ. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Molecular Medicine (Cambridge, Mass.). 17: 149-62. PMID 21170472 DOI: 10.2119/Molmed.2010.00180  0.756
2009 Volmar CH, Ait-Ghezala G, Frieling J, Weeks OI, Mullan MJ. CD40/CD40L interaction induces Abeta production and increases gamma-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Experimental Cell Research. 315: 2265-74. PMID 19422822 DOI: 10.1016/J.Yexcr.2009.04.023  0.76
2009 Mullan M, Quadros A, Patel N, Volmar C, Paris D. Improvement of cerebral blood flow and cognition in transgenic mouse models of Alzheimer's disease by nilvadipine Journal of the Neurological Sciences. 283: 260. DOI: 10.1016/J.Jns.2009.02.083  0.709
2008 Ait-ghezala G, Abdullah L, Volmar CH, Paris D, Luis CA, Quadros A, Mouzon B, Mullan MA, Keegan AP, Parrish J, Crawford FC, Mathura VS, Mullan MJ. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease. Cytokine. 44: 283-7. PMID 18835787 DOI: 10.1016/J.Cyto.2008.08.013  0.768
2008 Laporte V, Ait-Ghezala G, Volmar CH, Ganey C, Ganey N, Wood M, Mullan M. CD40 ligation mediates plaque-associated tau phosphorylation in beta-amyloid overproducing mice. Brain Research. 1231: 132-42. PMID 18606155 DOI: 10.1016/J.Brainres.2008.06.032  0.583
2008 Volmar CH, Ait-Ghezala G, Frieling J, Paris D, Mullan MJ. The granulocyte macrophage colony stimulating factor (GM-CSF) regulates amyloid beta (Abeta) production. Cytokine. 42: 336-44. PMID 18434187 DOI: 10.1016/J.Cyto.2008.03.007  0.59
2007 Ait-Ghezala G, Volmar CH, Frieling J, Paris D, Tweed M, Bakshi P, Mullan M. CD40 promotion of amyloid beta production occurs via the NF-kappaB pathway. The European Journal of Neuroscience. 25: 1685-95. PMID 17432959 DOI: 10.1111/J.1460-9568.2007.05424.X  0.604
2007 Volmar CH, Patel N, Quadros AN, Paris D, Mathura VS, Mullan M. Introduction to biological systems Bioinformatics: a Concept-Based Introduction. 1-11. DOI: 10.1007/978-0-387-84870-9_1  0.68
2006 Laporte V, Ait-Ghezala G, Volmar CH, Mullan M. CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models. Journal of Neuroinflammation. 3: 3. PMID 16504112 DOI: 10.1186/1742-2094-3-3  0.605
2006 Volmar C, Janczura KJ, Lambert G, Salah-Uddin H, Halley P, Sartor GC, Brothers SP, Wahlestedt C. P4-220: MULTIFACTORIAL EPIGENETIC STRATEGY FOR ALZHEIMER'S DISEASE Alzheimer's & Dementia. 14: P1527-P1527. DOI: 10.1016/J.Jalz.2018.07.041  0.536
2005 Ait-Ghezala G, Mathura VS, Laporte V, Quadros A, Paris D, Patel N, Volmar CH, Kolippakkam D, Crawford F, Mullan M. Genomic regulation after CD40 stimulation in microglia: relevance to Alzheimer's disease. Brain Research. Molecular Brain Research. 140: 73-85. PMID 16182406 DOI: 10.1016/J.Molbrainres.2005.07.014  0.773
2005 Mathura VS, Paris D, Ait-Ghezala G, Quadros A, Patel NS, Kolippakkam DN, Volmar CH, Mullan MJ. Model of Alzheimer's disease amyloid-beta peptide based on a RNA binding protein. Biochemical and Biophysical Research Communications. 332: 585-92. PMID 15896718 DOI: 10.1016/J.Bbrc.2005.04.164  0.737
2004 Todd Roach J, Volmar CH, Dwivedi S, Town T, Crescentini R, Crawford F, Tan J, Mullan M. Behavioral effects of CD40-CD40L pathway disruption in aged PSAPP mice. Brain Research. 1015: 161-8. PMID 15223380 DOI: 10.1016/J.Brainres.2004.05.004  0.686
Show low-probability matches.